[Cutaneous gene therapy: the graft takes].
Prospects of ex vivo cutaneous gene therapy rely on stable corrective gene transfer in epidermal stem cells followed by engraftment of corrected cells in patients. In the case of cancer prone genodermatoses, such as xeroderma pigmentosum, cells that received the corrective gene must be selected. However, this step is potentially harmful and can increase risks of immune rejection of grafts. These obstacles have recently been overcome thanks to the labeling of genetically modified stem cells using a small epidermal protein naturally absent in stem cells. This approach was shown to be respectful of the fate of epidermal stem cells that retained full growth and differentiation capacities, as well as their potential to regenerate normal human skin when grafted in a mouse model in the long term. These progresses now open realistic avenues towards ex vivo cutaneous gene therapy of cancer prone genodermatoses such as xeroderma pigmentosum. However, major technical improvements are still necessary to preserve skin appendages which would contribute to aesthetic features and comfort of patients.
Bergoglio
Valérie
V
Génomes et Cancers, CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France.
Warrick
Emilie
E
Chevallier-Lagente
Odile
O
Magnaldo
Thierry
T
D000818:Animals; D018929:Cell Culture Techniques; D015316:Genetic Therapy / Q000379:methods*; D006085:Graft Survival; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000637:transplantation; D051379:Mice; D012871:Skin Diseases / Q000235:genetics / Q000601:surgery*; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous; D014983:Xeroderma Pigmentosum / Q000235:genetics / Q000601:surgery*